ERBB2 and ovarian carcinoma: In advanced epithelial ovarian cancer, the association of HER2 overexpression with poor survival was first established in a study by Berchuck et al., where they evaluated 73 patients with HER2 overexpression who were found to have significantly worse survival as compared to patients with normal expression.